Palatin Technologies (FRA:PTN) Moat Score: 2/10 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PTN Palatin Technologies Inc FRA:PTN
19 GF Score
Price €3.30
! 5 Warning Signs
View Full Analysis

What is Palatin Technologies Moat Score?

Palatin Technologies FRA:PTN 19 Moat Score is 2 as of Jul. 26, 2026. GuruFocus rates FRA:PTN with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,395 Biotechnology companies, Palatin Technologies ranks better than 58.35% on this metric.

Palatin Technologies has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Palatin Technologies has No Moat: Palatin Technologies has limited market share and lacks significant intellectual property or brand strength. The biotech industry is highly competitive, and the company does not possess durable cost advantages or regulatory barriers, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Palatin Technologies might have No Moat - Very weak/transient advantages.

Palatin Technologies  (FRA:PTN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Palatin Technologies Moat Score Related Terms

FRA:PTN vs LPCN, NCEL, CLRB: Moat Score Comparison

For the Biotechnology subindustry, Palatin Technologies's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palatin Technologies Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Moat Score distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Moat Score falls into.


FRA:PTN
19GF Score
Palatin Technologies Inc FRA:PTN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Palatin Technologies (FRA:PTN) has a Moat Score of 2 as of Jul. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Palatin Technologies ranks #581 out of 1395 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Palatin Technologies' Moat Score too high?
Palatin Technologies' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Palatin Technologies' value of 2 is 0% at this industry median. Based on the distribution chart, Palatin Technologies ranks #581 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Palatin Technologies has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Palatin Technologies' Moat Score compare to LPCN and NCEL?
According to the Biotechnology industry distribution chart, Palatin Technologies ranks #581 out of 1395 companies for Moat Score. This puts Palatin Technologies in the upper half of its industry. The industry median Moat Score is 2.00. Palatin Technologies' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Palatin Technologies's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Palatin Technologies's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palatin Technologies stock overvalued right now?
Palatin Technologies (FRA:PTN) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Palatin Technologies' overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Palatin Technologies (FRA:PTN), the current Moat Score is 2 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palatin Technologies Business Description

Other Exchanges PTN:USA0KF3:UK
Address 103 Carnegie Center Drive, Suite 300, Princeton, NJ, USA, 08852
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
19GF Score

Get the complete analysis for FRA:PTN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.30
Price